EU orders Illumina to pay $476M fine over unapproved Grail deal
Illumina must pay a €432 million ($476 million) fine for buying the cancer-testing firm Grail without regulatory approval, the European Commission said today.
The San …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.